Drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use

Immunotherapy is an expanding area of cancer treatment with significant promise. Despite their efficacy, checkpoint inhibitors are associated with a number of immune‐related adverse events; here, we described thrombocytopenia secondary todurvalumab. Immunotherapy is an expanding area of cancer treat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical Case Reports 2021-06, Vol.9 (6), p.e04227-n/a
Hauptverfasser:	Dougherty, Sean C., Lynch, Alia C., Hall, Richard D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigens Asymptomatic Blood Blood platelets Cancer therapies Case Report Case Reports Chemotherapy Drug therapy Epistaxis Hemoglobin Immunoglobulin G Immunotherapy Ipilimumab ITP Ligands Lung cancer Lung cancer, Non-small cell medical oncology Monoclonal antibodies Pemetrexed pharmacokinetics platelets—acquired platelet disorders Purpura Radiation Steroids T cells Thrombocytopenia
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Immunotherapy is an expanding area of cancer treatment with significant promise. Despite their efficacy, checkpoint inhibitors are associated with a number of immune‐related adverse events; here, we described thrombocytopenia secondary todurvalumab. Immunotherapy is an expanding area of cancer treatment with significant promise. Despite their efficacy, checkpoint inhibitors are associated with a number of immune‐related adverse events; here, we described thrombocytopenia secondary todurvalumab.
ISSN:	2050-0904 2050-0904
DOI:	10.1002/ccr3.4227